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The widely held view that SLN (sarcolipin) would be the natu-
ral inhibitor of SERCA1 (sarcoplasmic/endoplasmic-reticulum
Ca2+-ATPase 1), and PLB (phospholamban) its counterpart for
SERCA2 inhibition is oversimplified and partially wrong. The
expression of SLN and PLB mRNA and protein relative to
SERCA1 or SERCA2 was assessed in ventricle, atrium, soleus
and EDL (extensor digitorum longus) of mouse, rat, rabbit and pig.
SLN protein levels were quantified by means of Western blotting
using what appears to be the first successfully generated antibody
directed against SLN. Our data confirm the co-expression of PLB
and SERCA2a in cardiac muscle and the very low levels (in
pig and rabbit) or the absence (in rat and mouse) of PLB protein
in the slow skeletal muscle. In larger animals, the SLN mRNA
and protein expression in the soleus and EDL correlates with
SERCA1a expression, but, in rodents, SLN mRNA and protein
show the highest abundance in the atria, which are devoid of
SERCA1. In the rodent atria, SLN could therefore potentially
interact with PLB and SERCA2a. No SLN was found in the
ventricles of the different species studied, and there was no com-
pensatory SLN up-regulation for the loss of PLB in PLB−/−
mouse. In addition, we found that SLN expression was down-
regulated at the mRNA and protein level in the atria of hyper-
trophic hearts of SERCA2b/b mice. These data suggest that super-
inhibition of SERCA by PLB-SLN complexes could occur in the
atria of the smaller rodents, but not in those of larger animals.
Key words: atrium, cardiomyopathy, phospholamban, sarcolipin,
sarcoplasmic/endoplasmic-reticulum Ca2+-ATPase (SERCA),
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INTRODUCTION
PLB (phospholamban) and SLN (sarcolipin) are two small homo-
logous intrinsic membrane proteins (respectively comprising 52
and 31 amino acid residues) which are confined to the endoplasmic
reticulum or the sarcoplasmic reticulum. Both proteins can inhibit
the SERCA (sarcoplasmic/endoplasmic-reticulum Ca2+-ATPase)
activity by lowering the apparent Ca2+ affinity of the pump [1].
When both PLB and SLN are co-expressed in vitro, their inhibi-
tory effect becomes synergistic, leading to superinhibition of the
pump. This can be partially attributed to the ability of SLN to dis-
rupt PLB pentamers, leading to an increase in the amount of PLB
monomers, the inhibitory form of PLB [2]. Also, recent modell-
ing studies suggest that PLB and SLN could bind side-by-side in
a lateral groove of SERCA1 forming a more stable complex than
in the absence of SLN [3]. This tighter binding would explain part
of the superinhibition of SERCA [3].
Studies, mainly on rabbits, have led to the widely accepted view
that PLB is expressed predominantly in cardiac and slow-twitch
skeletal muscle, where it regulates the SERCA2a isoform of cal-
cium pumps, whereas, in fast-twitch muscle, SLN represents the
corresponding regulator of SERCA1 [4]. However, several recent
observations suggest that this picture is over-simplified.
Minamisawa et al. [5] showed recently that SLN was expressed
at the mRNA level in the mouse atria in the absence of significant
SERCA1 levels. SLN and PLB can interact in vitro with SERCA1
and SERCA2a, affecting their apparent Ca2+ affinity to the same
extent [2]. Moreover, the synergistic action of SLN and PLB
on SERCA activity and the recent modelling studies suggest a
physiological role for SLN and PLB co-expression. However,
only fragmentary data are available on the relative co-expression
of SLN and PLB mRNA in various muscles, and there is an almost
complete lack of such information at the protein level. This
information is necessary in order to assess the full physiological
implications of potential synergistic interaction of both regulators.
This prompted us to specifically look out for potential co-ex-
pression of SLN and PLB in vivo. Therefore a more general study
of the relative expression of SLN and PLB in relation to SERCA
in different muscles of small and large animals was undertaken.
Recent studies have shown that SLN mRNA is present in the
heart, notably where PLB is abundantly expressed, and suggested
that changes in SLN expression might alter cardiac function in
several cardiomyopathies. Indeed, SLN mRNA was found in hu-
man [6], mouse [5] and rat atria [7], but not in the ventricle.
Furthermore, it was recently shown that SLN mRNA is down-
regulated in atria of patients with chronic atrial fibrillation [8] and
in atria of activated H-Ras transgenic mice [5]. Thus altered SLN
expression may contribute to different Ca2+ handling in cardiac
disease. However, comparing SLN mRNA levels may only give
a partial, possibly even misleading, picture. Several studies have
shown that the expression of PLB must be strongly controlled at
the protein level [9–10]. A similar post-transcriptional control of
SLN expression might exist. Therefore the present study included
both mRNA and protein assays.
EXPERIMENTAL
Animals
All animal experimentation was performed in accordance with
approved protocols of the local ethics committee and conforms
Abbreviations used: EDL, extensor digitorum longus; NF-SLN, sarcolipin tagged N-terminally with a FLAG epitope; PLB, phospholamban; RPA, RNase-
protection assay; RT, reverse transcription; SERCA, sarcoplasmic/endoplasmic-reticulum Ca2+-ATPase; SLN, sarcolipin; WT, wild-type.
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to the Guide for the Care and Use of Laboratory Animals of the
NationalAcademyofSciences (http://www.nap.edu/readingroom/
books/labrats/). The animals used in the present study were:
adult mice (strain 129sV/Swiss 50/50, 12 weeks old), adult rats
(Wistar, 15 weeks old), young adult rabbits (White New Zealand,
3 months old, 3.5 kg) and young domestic pigs (27–32 kg;
Seghers GenTech, Lebbeke, Belgium).
RT (reverse transcription) PCR
Total RNA was isolated from EDL (extensor digitorum longus)
(fast-twitch skeletal muscle), soleus (slow-twitch skeletal
muscle), atria and ventricles from mouse, rat, rabbit and pig using
the TRIzol® method (Invitrogen). RNA was treated with DNase I
to avoid genomic DNA contamination. cDNA was prepared from
1 µg of RNA in a final volume of 20 µl according to the manu-
facturer’s protocol (Thermoscript RT-PCR kit; Invitrogen). The
amount of cDNA mixture for PCR was adjusted to obtain equal
levels of SERCA for each tissue. Negative controls without
reverse transcriptase were tested for each sample. Primers were
designed for SLN, PLB and SERCA1/2 of mouse, rat, rabbit and
pig (Supplementary Table A at http://www.BiochemJ.org/bj/389/
bj3890151add.htm). The number of cycles was chosen to fall in
the exponential phase of amplification. The SERCA primers were
designed to co-amplify SERCA1 and SERCA2 with the same
efficiency. SERCA1 and SERCA2 each contain a different unique
restriction site in the amplified product (Supplementary Table B
at http://www.BiochemJ.org/bj/389/bj3890151add.htm). Hence,
the relative contribution of both isoforms could be assessed after
restriction analysis of the PCR product.
RPA (RNase-protection assay)
To check mRNA levels in different mouse models, we generated
a 111-nucleotide SLN RNA probe which we used for RPA.
Therefore we cloned the SLN coding region in a pGEMTeasy
vector and linearized it with SpeI. T7 RNA polymerase was added
with α-32P-radiolabelled UTP to create an antisense probe. A
standard RPA protocol was used as described previously [9].
Production of anti-SLN antibodies
A peptide (MERSTQELFINFC) corresponding to the 12-residue-
long cytosolic part of mouse/rat SLN with an additional cysteine
added to its C-terminus was conjugated to keyhole-limpet haemo-
cyanin. Rabbits were immunized with this antigen, and the
serum obtained was designated SLN78. For affinity purification,
the immunizing peptide was coupled to AF-Amino Toyopearl
650 M. The bound antibodies were eluted from the affinity gel
with 100 mM glycine (pH 2.5). The affinity-purified antibodies
were designated SLNAP78. Both antibody production and affinity
purification occurred at Eurogentec (Seraing, Belgium).
Western-blot analysis
Isolated tissue from EDL, soleus, atria and ventricles of mouse,
rat, rabbit and pig were homogenized in a buffer containing
10 mM imidazole (pH 7.0), 300 mM sucrose and CompleteTM
protease inhibitor cocktail (Roche). For mouse atria, soleus and
EDL, tissue was pooled from six animals. Protein concentration
was determined using the BCA (bicinchoninic acid) kit (Pierce).
Amounts of homogenates were adjusted to obtain equal SERCA
loading for each tissue. Samples were separated on 4–12% Bis-
Tris gradient gels (NuPAGETM electrophoresis system; Invitrogen)
and blotted on to PVDF membranes (0.22 µm; Bio-Rad) accord-
ing to the manufacturer’s protocol. Blots were probed with a poly-
clonal antiserum for SLN78 (1:500), an affinity-purified
polyclonal anti-SLN antibody (SLNAP78, 1:200), a monoclonal
anti-PLB antibody (mA1, 1:20000, Upstate Biotechnology) and
with a home-made pan-specific polyclonal anti-SERCA antibody
TRY2 (1:2000) [11]. Detection was performed with alkaline-
phosphatase-coupled secondary antibodies, using the Vistra en-
hanced chemifluorescence system (Amersham Biosciences).
Preparation of SERCA, SLN and PLB standards
SERCA was enriched from rabbit EDL. Homogenates were frac-
tionated at 4 ◦C for 20 min at 1000 g, 20 min at 15000 g and
30 min at 200000 g. Microsomes were treated further with 0.6 M
KCl and 100 mM Na2CO3 (pH 11). SLN was purified from pig
EDL by the procedure of Ohnoki and Martonosi [12]. Briefly,
a microsomal fraction was prepared which was treated further
with 9 vol. of methanol. Acidified methanol/chloroform (2:1, with
10 mM HCl) was added to the residue and 5 vol. of cold diethyl
ether were used to precipitate the crude proteolipid fraction.
Finally, SLN was extracted with and stored in n-butanol at −80 ◦C.
The identity and purity of the extract was confirmed by SDS elec-
trophoresis and N-terminal amino acid sequence analysis (Edman
degradation), which was performed on a Procise 492 micro-
sequencer (Applied Biosystems) running in pulsed liquid mode.
The sample was loaded on to a polybrene-coated glass fibre disc,
previously pre-cycled four times. To obtain a protein standard
for PLB, PLB was extracted from rabbit ventricle according to
the butanol extraction method of Ohnoki and Martonosi [12], as
described for the purification of SLN. We observed that PLB co-
extracted with SLN from tissue that contains both proteins. The
purity of the PLB extract was analysed on a polyacrylamide gel,
stained with Sypro Orange (Invitrogen). The amounts of SERCA,
PLB and SLN were compared with a known amount of BSA
and GST (glutathione S-transferase) on a gel stained with Sypro
Orange. The fluorescent signal was visualized with a Storm840
FluorImager (Amersham Biosciences).
Statistics
Data shown are means +− S.E.M. Statistical analysis was per-
formed using Student’s t test or by ANOVA followed by
Bonferroni’s t test. P < 0.05 is considered to be significant.
RESULTS
Levels of SLN and PLB mRNA normalized to those of SERCA
Mainly because antibodies directed against SLN were previously
unavailable, and because the systematic quantification of the SLN
proteolipid via butanol extraction is cumbersome, earlier studies
on SLN expression only assessed the relative expression levels of
its mRNA [5]. In a first series of experiments, we therefore also
measured the mRNA levels of SLN and PLB in total RNA extracts
from cardiac ventricle, cardiac atrium, slow-twitch soleus and
fast-twitch EDL from mice, rats, rabbits and pigs by means of
RT-PCR. Since SLN and PLB act as regulators of SERCA,
the relative expression levels of SLN and PLB mRNA were
normalized to those of SERCA. Hence, the amount of total input
RNA in the RT-PCR assay of SLN and PLB was adjusted to
yield equal SERCA signals in parallel assays. The obtained SLN/
SERCA and PLB/SERCA mRNA ratios were expressed as per-
centages of the ratio obtained for atria, tissue that contains both
SLN and PLB mRNA. According to their fibre-type composition,
muscles express SERCA1 or SERCA2, or a mixture of both.
Therefore the primers used in the RT-PCR were designed to
co-amplify SERCA1 and SERCA2 cDNA with the same ef-
ficiency. The relative expression levels of SERCA1 and SERCA2
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Figure 1 Determination of SLN/SERCA and PLB/SERCA mRNA ratios using RT-PCR
The amount of cDNA used for amplification was adjusted to yield equal amounts of SERCA. The panels in (I) show representative examples of RT-PCR on cDNA of different muscle types
(V, ventricles; A, atria; S, soleus; E, EDL). Four different species, as indicated, were analysed in parallel. The primers and PCR conditions summarized in Supplementary Table A (http://
www.BiochemJ.org/bj/389/bj3890151add.htm) were used to determine expression levels of SLN, PLB and SERCA. The panels in (II) summarize the PLB/SERCA (grey) or SLN/SERCA (white)
mRNA ratio represented as mean percentage (+−S.E.M.) compared with atrial levels. For mouse, tissue was pooled from six different animals to prepare total RNA (n = 2). For other species, n = 3.
#SLN/SERCA mRNA ratio significantly different (P < 0.05) compared with atria. *PLB/SERCA mRNA ratio significantly different (P < 0.05) compared with atria. VENTR, ventricles.
Table 1 Summary of SERCA, SLN and PLB mRNA expression levels
Summary of data presented in Figure 1. Relative ratios of SLN/SERCA (a) and PLB/SERCA
(b) normalized to the average percentage of atria as determined by RT-PCR. For mouse, tissue
was pooled from six different animals to prepare total RNA (n = 2). For other species, n = 3.
Analysis was performed in triplicate. Results are expressed as means +− S.E.M. N.D., none
detected.
(a) SLN/SERCA mRNA ratios
Tissue Mouse Rat Rabbit Pig
Ventricles N.D.† N.D.† N.D.† 0.5 +− 0.2†
Atria 100.0 +− 10.7 100.0 +− 5.9 100.0 +− 12.8 100.0 +− 19.4
Soleus 32.7 +− 3.1† 5.9 +− 0.1† 110.8 +− 15.6 524.2 +− 35.3†
EDL N.D.† N.D.† 144.4 +− 15.4 556.7 +− 2.1†
(b) PLB/SERCA mRNA ratios
Tissue Mouse Rat Rabbit Pig
Ventricles 140.8 +− 12.1 176.1 +− 35.0* 188.5 +− 30.2* 169.1 +− 65.4
Atria 100.0 +− 33.7 100.0 +− 0.7 100.0 +− 0.2 100 +− 28.0
Soleus 27.2 +− 11.3* N.D.* 54.2 +− 19.8 32.2 +− 18.0*
EDL 5.2 +− 1.4* 0.7 +− 0.5* 4.5 +− 1.3* 21.4 +− 1.5*
†SLN/SERCA mRNA ratio significantly different (P < 0.05) compared with atria.
* PLB/SERCA mRNA ratio significantly different (P < 0.05) compared with atria.
were then determined by restriction analysis of the amplified
DNAs as detailed in Supplementary Table B (http://www.
BiochemJ.org/bj/389/bj3890151add.htm).
The results depicted in Figure 1 and Table 1 confirm the general
view that SLN mRNA is highly expressed in the fast-twitch EDL
of rabbit and, furthermore, now also indicates that this is also the
case for the pig EDL. Remarkably, the expression of SLN relative
to SERCA is nearly as high in the slow-twitch soleus of rabbit and
pig. Surprisingly, in the smaller animals, such as rat and mouse, no
SLN mRNA was detected in EDL. Instead, both rodents express
small amounts of SLN mRNA in the soleus, but clearly show the
highest SLN mRNA levels in the cardiac atria, a tissue that does
not express SERCA1. High SLN mRNA expression levels in the
murine and rat atria have been reported earlier [5,7]. Furthermore,
it is clear that the ventricle does not contain SLN.
The PLB/SERCA mRNA ratio of all four animal species is the
highest in ventricle and the lowest in EDL. For rabbit and pig,
this corresponds roughly to a complementary expression pattern
as compared with that of SLN mRNA (Figure 1 and Table 1).
Figure 2 and Table 2 show the percentages of SERCA2 and
SERCA1 mRNA compared with total SERCA mRNA expression
levels for the different animal species. Conforming to the general
expectation, with the notable exception of the pig, SERCA1 is
most highly expressed in fast-twitch EDL of all species. In the
slow-twitch soleus SERCA2 mRNA prevails in all four species.
Characterization of the anti-SLN antibody
We raised a rabbit antiserum (SLN78) against the cytosolic part
(i.e. the peptide comprising the first 12 amino acids counting from
the N-terminal side) of the rat/mouse SLN. A cysteine residue
was added to the C-terminus of the antigen peptide to link it to
keyhole-limpet haemocyanin as a carrier protein. These antibodies
were used for Western blotting. To convert relative expression
levels of SLN, PLB and SERCA into absolute values, SLN,
PLB and SERCA proteins were purified and used as an absolute
standard. Purified SLN was obtained from pig EDL via the butanol
extraction method (Figure 3A, lane I), and its protein sequence
was confirmed by direct sequencing (Edman degradation).
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Figure 2 Determination of SERCA isoforms using ratio PCR
Mouse (A), rat (B), rabbit (C) and pig (D) were analysed in parallel. The amount of cDNA used for RT was adjusted to yield equal amounts of total SERCA. Following PCR, restriction digestion
(see enzymes in Supplementary Table A at http://www.BiochemJ.org/bj/389/bj3890151add.htm) was performed to discriminate between SERCA1 and SERCA2. The panels in (I) show representative
examples of ratio PCRs on cDNA of different muscle types (V, ventricles; A, atria; S, soleus; E, EDL). The panels in (II) summarize the data expressed as the means (+−S.E.M.) of percentage
SERCA1/total SERCA (grey) or percentage SERCA2/total SERCA (white) mRNA ratios. Mouse tissue was pooled from six different animals to prepare total RNA (n = 2). For other species, n = 3.
VENTR, ventricles.
Table 2 Summary of ratio PCR of different SERCA isoforms
Summary of data presented in Figure 2. Results are the percentage SERCA2 (a) and percentage
SERCA1 (b) of total SERCA (SERCAtot) mRNA levels per tissue per species. For mouse, tissue
was pooled from six different animals to prepare total RNA (n = 2). For other species, n = 3.
Analysis was performed in triplicate. Results are expressed as means +− S.E.M. N.D., none
detected.
(a) Percentage SERCA2/SERCAtot
Tissue Mouse Rat Rabbit Pig
Ventricles 99.8 +− 0.4 99.8 +− 1.3 100.0 99.5 +− 0.4
Atria 99.7 +− 0.6 99.2 +− 1.2 100.0 100.0
Soleus 58.0 +− 2.8 70.5 +− 7.6 55.7 +− 4.1 73.1 +− 2.0
EDL 2.5 +− 2.4 6.3 +− 4.5 25.7 +− 1.3 60.0 +− 8.1
(b) Percentage SERCA1/SERCAtot
Tissue Mouse Rat Rabbit Pig
Ventricles 0.3 +− 0.3 0.2 +− 0.2 N.D. 0.5 +− 0.4
Atria 0.3 +− 0.2 0.8 +− 0.7 N.D. N.D.
Soleus 42.0 +− 2.8 29.5 +− 7.6 44.3 +− 4.1 26.9 +− 2.0
EDL 98.5 +− 4.0 93.7 +− 6.3 74.3 +− 1.3 40.0 +− 8.1
Notably, on a Western blot, no PLB could be detected in the
purified SLN fraction (Figure 3A, lane II). The SLNAP78
antibody recognizes purified SLN on a Western blot, as indicated
in lane III of Figure 3(A), and addition of the antigen peptide in
solution suppresses the antibody-SLN binding (Figure 3B,
lanes IV and V). Unfortunately, the anti-SLN antibody can cross-
react with PLB, as indicated in Figure 3(C), lanes VI and VII. The
extra cysteine residue on the antigen peptide of SLN causes greater
sequence similarity with PLB and might therefore favour this
unwanted cross-reaction of the antibody (Figure 3D). Our Western
blots of PLB−/− and SERCA2b/b atria depicted in Figure 6(C) indi-
cate further that the anti-SLN antibodies cross-react with PLB.
Indeed, the additional band with lower mobility that reacts
positively with anti-SLN antibodies is absent in PLB−/− and
becomes more pronounced in SERCA2b/b mice that respectively
lack or show up-regulation of PLB. Furthermore, when the blots
were stained in parallel for PLB (Figure 6C), the expression levels
of PLB correlate nicely with the strength of the upper band.
Preparation of the SERCA, SLN and PLB standards
SERCA, SLN and PLB were respectively enriched from rabbit
EDL, pig EDL and rabbit ventricle. The purity of the standards
was verified by gel electrophoresis stained with Sypro Orange
(Figures 4A–4C). The concentrations of the standards were
determined by comparison with a BSA and GST standard.
The identity of the bands was confirmed by Western blotting.
To identify SERCA on a Western blot, we used a pan-specific
antibody (TRY2, epitope PDPRAVNQDKKN [11]) which does
not discriminate between SERCA1 and SERCA2.
The levels of SLN protein normalized to those of SERCA
In order to assess the relative expression levels of SLN protein in
the different muscle types by means of Western blotting, we adjus-
ted the loads of homogenates applied to the electrophoresis gel to
yield identical signals of SERCA. This was verified by immuno-
staining. In parallel, Western blots with the same ratios of protein
loading were immunostained for SLN and PLB (Figure 5). The
results of these analyses are summarized in Table 3. Table 3(a)
expresses the amounts of SERCA per mg of protein content of
the different muscle homogenates. As expected, the fast-twitch
skeletal muscles express the highest relative amounts of SERCA.
Except for mouse, homogenates from atrium contain 2–3-fold
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Figure 3 Characterization of the anti-SLN antibody
(A) Purified SLN (0.1 µg) was visualized with Sypro Orange after SDS/PAGE (lane I). After transfer on to a PVDF membrane, the SLNAP78 antibody recognizes the purified SLN (lane III). No PLB is
present in the purified SLN (lane II) as shown by incubation of the blot with an anti-PLB antibody. (B) Addition of antigenic peptide in solution (+) during primary antibody incubation (lane V) can
reduce the antibody reaction with purified SLN (−) (lane IV). (C) The SLNAP78 antibody cross-reacts with PLB. Homogenate of mouse atria (70 µg) was transferred to a blot and stained in parallel
with the SLNAP78 (lane VI) and anti-PLB antibody (lane VII). PLB (apparent molecular mass 5 kDa) and SLN (apparent molecular mass 4 kDa) were discriminated by size. (D) Comparison of the
amino acid sequence of homologous parts of PLB, SLN and the epitope used to develop anti-SLN antibodies. Bold and underlined amino acids are identical with the epitope. As indicated by the two
rectangles, the C-terminal part of the PLB sequence shows striking similarity to the corresponding mouse and rat SLN sequence, and to the epitope.
more SERCA than ventricle homogenates, which is again in line
with earlier reports [13].
Table 3(b) gives the calculated molar ratios of SLN/SERCA
for the four different types of muscle in each of the four animal
species. SLN protein was not detected in any of the cardiac ven-
tricles. It fell also below the detection limit in the skeletal muscles
of mouse and rat, but was clearly expressed in both the fast- and
slow-twitch muscle of rabbit and pig. In EDL of pig and rabbit,
there was a nearly 3-fold excess of SERCA over SLN. Remark-
ably, rabbit soleus showed a higher SLN/SERCA molar ratio
than the fast-twitch EDL, but because EDL contains relatively
more SERCA than soleus, the absolute SLN content in EDL is still
approx. 3-fold higher compared with soleus. The highest SLN/
SERCA ratios (1.2–1.6-fold molar excess of SLN over SERCA)
are found in atria of rat and mouse. In contrast with the mRNA
data, SLN protein was not detected in the atria of rabbit and pig.
The levels of PLB protein normalized to those of SERCA
Of all the muscles studied, ventricles expressed the highest PLB
protein levels (Figure 5). Table 3(c) displays the PLB/SERCA
molar ratios. The highest ratio was found in the ventricles in all
species. The expression levels in atria amount to only approx. two-
thirds of those in the ventricle of pig and rabbit and to only approx.
one-third in the rat and mouse. In the larger animals (pig and
rabbit), the amount of PLB protein in the slow-twitch muscle
amounts to only a few percent of the corresponding value in ven-
tricles. In EDL, PLB levels are even lower. PLB protein levels
fell below detection levels in skeletal muscles (whether slow- or
fast-twitch) of rat and mouse. The SLN/PLB molar ratios are
presented in Table 3(d). In the atria of rat and mouse, but also
in the soleus of rabbit, absolute levels of PLB are approx. 2-fold
higher than of SLN. In the EDL of rabbit and pig, there is a
3–5-fold molar excess of SLN over PLB.
SLN expression in two different mouse models
PLB−/− mice are among the most intensely studied mouse models
and are characterized by a hyperdynamic state of the heart [14].
To date, it had not been investigated whether the loss in the
PLB protein caused any compensatory up-regulation in SLN ex-
pression in the ventricles or atria. Therefore we checked both
mRNA and protein SLN levels in the ventricles and the atria of
PLB−/−. As shown in Figure 6, no difference in SLN expression
levels could be found either at the mRNA [Figure 6A, WT (wild-
type) 100 +− 8.9% compared with PLB−/− 98.4 +− 13.6%;
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Figure 4 Purified SLN (A), PLB (B) and SERCA (C) proteins were evaluated
by SDS/PAGE after staining with Sypro Orange
In parallel, SLN, PLB and SERCA were identified via Western blotting (WB) using the SLNAP78,
mA1 and TRY2 antibodies respectively. To determine the absolute amount of SLN, PLB and
SERCA in the standard, the intensity of the purified protein bands on the Sypro-Orange-stained
gel were compared with two protein standards of known concentrations: BSA and GST. On
the gels, the amounts of BSA and GST are indicated in µg. Serial dilutions (:3) of SLN, PLB
and SERCA were analysed.
P > 0.05] or at the protein level (Figure 6C, WT 100 +− 21.7%
compared with PLB−/− 79.3 +− 11.2%; P > 0.05).
It has been shown previously that SLN mRNA levels decrease in
the atria of activated H-Ras transgenic mice, which is a model for
left ventricular hypertrophy [5]. This prompted us to investigate
the SLN levels in SERCA2b/b mice, which also develop concentric
ventricular hypertrophy [9]. SERCA2b/b mice, in which the Atp2a2
(SERCA2) gene is modified such that SERCA2a-specific splicing
is excluded, express only SERCA2b in atria and ventricles, instead
of the usual SERCA2a. These mice are marked with an increased
cardiac expression of PLB at the protein level (Figure 6C).
Figure 6(B) shows that the SERCA2b/b mice express less SLN in
the atria both at the mRNA (Figure 6B, 64.3 +− 17.9% compared
with WT, P < 0.05) and protein level (Figure 6C, 59.3 +− 8.9
compared with WT, P < 0.05). Again, in the ventricles, no SLN
expression could be found.
Figure 5 Western-blot analysis of total homogenates of different muscle
types (V, ventricles; A, atria; S, soleus; E, EDL) of (A) mouse, (B) rat,
(C) rabbit and (D) pig
The amount of protein on the gel was adjusted to yield equal amounts of SERCA on a Western
blot stained with TRY2 anti-SERCA antibody (I). Anti-SLN (II) and anti-PLB antibody (III) were
used to stain parallel Western blots loaded with the same relative protein ratios. Cross-reaction
of the anti-SLN antibody with PLB is indicated in (II). To estimate the amount of SLN, PLB
and SERCA, samples were compared with an absolute standard for SLN, PLB and SERCA.
Results are presented in Table 3. Mouse tissue was pooled from six different animals to prepare
homogenates (n = 2). For other species, n = 3.
DISCUSSION
Anti-SLN antibody recognizes SLN
In vitro studies have shown that PLB and SLN can form a super-
inhibitory ternary complex with SERCA, but it is still in debate
whether this could be physiologically relevant in vivo [2]. In
that respect, it was of particular interest to look for potential
co-expression of SLN and PLB in vivo. Therefore we examined
four different muscle types from four animal species and deter-
mined SLN, PLB and SERCA at both the mRNA and protein
levels. Previous attempts to make an anti-SLN antibody were
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Table 3 Summary of SERCA, SLN and PLB protein expression levels
(a) Amount of SERCA in µg per mg of protein of tissue homogenate. Levels were obtained by
comparison of the amount of SERCA on a Western blot with an absolute SERCA standard as
shown in Figure 4. The SERCA levels in µg were corrected per mg of protein loaded on to the
blot. (b) Absolute quantification of SLN and SERCA via Western blotting (Figure 4) permitted
the calculations of SLN/SERCA molar ratios (molecular mass of mouse SLN = 3807.27 g/mol
and molecular mass of SERCA1 and SERCA2 = 112 575.2 g/mol). (c) Absolute quantification
of PLB via Western blotting (Figure 4) permitted the calculations of PLN/SERCA molar ratios
(molecular mass of rabbit PLB = 6094.28 g/mol). (d) SLN/PLB molar ratios are presented as
means +− S.E.M. For mouse, tissue was pooled from six different animals to prepare total RNA
(n = 2). For other species, n = 3. N.D., none detected; N.A., not applicable.
(a) µg of SERCA/mg of protein
Tissue Mouse Rat Rabbit Pig
Ventricles 8.8 +− 0.7 3.9 +− 0.1 2.15 +− 0.0 3.5 +− 0.1
Atria 9.9 +− 0.9 9.9 +− 0.3 6.1 +− 0.0 7.8 +− 0.3
Soleus 16.3 +− 0.1 18.8 +− 1.0* 13.9 +− 1.3 15.2 +− 0.2*
EDL 141.8 +− 3.4* 64.9 +− 2.8* 96.8 +− 7.1* 43.3 +− 0.8*
(b) mol of SLN/mol of SERCA
Tissue Mouse Rat Rabbit Pig
Ventricles N.D. N.D. N.D. N.D.
Atria 1.24 +− 0.25 1.61 +− 0.24 N.D. N.D.
Soleus N.D. N.D. 0.87 +− 0.21 0.25 +− 0.06
EDL N.D. N.D. 0.37 +− 0.07 0.41 +− 0.05
(c) mol PLB/mol SERCA
Tissue Mouse Rat Rabbit Pig
Ventricles 5.1 +− 0.5 10.9 +− 2.3 22.5 +− 1.8 6.7 +− 0.2
Atria 1.5 +− 0.5* 3.3 +− 0.9* 13.1 +− 3.8* 4.3 +− 0.3*
Soleus N.D. N.D. 1.35 +− 0.9* 0.2 +− 0.1*
EDL N.D. N.D. 0.14 +− 0.05* 0.08 +− 0.01*
(d) molar ratio SLN/PLB
Tissue Mouse Rat Rabbit Pig
Ventricles N.A. N.A. N.A. N.A.
Atria 0.84 +− 0.33 0.49 +− 0.15 N.A. N.A.
Soleus N.A. N.A. 0.64 +− 0.35 1.2 +− 0.58
EDL N.A. N.A. 2.74 +− 1.04 5.1 +− 1.05
*Significantly different compared with ventricles (P < 0.05).
unsuccessful, and the lack of anti-SLN antibodies limited expres-
sion studies at the protein level [4,7]. To circumvent the need for
anti-SLN antibodies, earlier studies made use of a N-terminally
FLAG-labelled SLN (NF-SLN) instead of SLN to track its ex-
pression in HEK-293 (human embryonic kidney) cells or isolated
cardiomyocytes [2,4,7]. But a disadvantage of the presence of the
N-terminal FLAG is that it might change the behaviour of SLN.
Now, for the first time, anti-SLN antibodies were generated which
enabled us to quantify endogenous SLN protein levels in tissue
homogenates. These antibodies were proved to recognize purified
SLN. Because technical details of previous attempts were un-
published, it is not clear why this attempt to produce anti-SLN
antibodies was more successful.
Besides SLN of rodents, the anti-SLN antibody also recognizes
SLN of rabbit and pig, which may be explained by significant se-
quence similarity: MERSTXELXXNF. The differences in the
SLN sequence might, however, result in a weaker antibody reac-
tion with SLN of rabbit and pig than with SLN of rodents. This
might limit the detection of SLN in rabbit and pig tissues (e.g.
in the atria). A caveat in the estimation of absolute SLN levels is
that purified SLN from pig was used as a standard for measuring
Figure 6 Representative examples of the relative quantification of SLN
mRNA and protein expression in atria or ventricle of PLB−/− and SERCA2b/b
RPA was performed to estimate SLN mRNA levels in atria or ventricle of PLB−/− (A) and
SERCA2b/b (B). (C) After Western blotting (WB) of 60 µg homogenates, the SLNAP78 antibody
was used to determine relative SLN protein levels in atria of PLB−/− and SERCA2b/b . In
parallel, blots were stained with the anti-PLB antibody mA1. (D) Summary of the SLN mRNA,
SLN protein and PLB protein expression levels. Atria were pooled from six to eight different
animals to prepare total RNA or homogenates. Analysis was performed in triplicate. Results are
mean percentages +− S.E.M. of expression compared with WT. *Significantly different compared
with WT (P < 0.05).
SLN levels in other species. The probably lower sensitivity of the
anti-SLN antibodies for rabbit SLN than for rodent SLN might
lead to overestimation of SLN levels in mouse and rat.
Anti-SLN antibodies also cross-react with PLB, which can only
be due to the common LXXNFC motif. Although the similarity
between PLB and the SLN epitope is small, even the weakest
cross-reaction may appear significant in tissues where PLB is
abundantly expressed, such as in ventricle and atria. Taken to-
gether, the specificity of these antibodies for SLN is not absolute,
which hampers their use in ELISA and in immunocytochemical
assays, but they were proved to be useful for semi-quantitative
Western-blot analysis (allowing discrimination of SLN and PLB
by size).
PLB is the main regulator of SERCA2a
For all species tested, it was clear that the PLB/SERCA mRNA
and protein ratios decrease from ventricle to atria, soleus and EDL.
This correlates roughly with the relative expression levels of
SERCA2a in these tissues. Remarkably, whereas low levels
of PLB mRNA were detected in soleus and EDL of mouse, rabbit
and pig (but not of rat), PLB protein could only be found in
soleus and EDL of rabbit and pig, and not in skeletal muscle of
mouse and rat. These observations are in line with earlier reports
on absence of PLB protein from the soleus in rat [15]. The docu-
mented faster relaxation of the soleus in PLB−/− mice compared
with control animals therefore seems related to an indirect effect
[16].
In vivo, SLN can be co-expressed with SERCA1 and SERCA2
Results of the present study confirm earlier work which showed
SLN mRNA expression in the atria of mouse [5] and rat [7],
and in the soleus and EDL of rabbit. These findings are now ex-
tended to the protein level. The signal generated with our antibody
c© 2005 Biochemical Society
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on Western blots roughly correlates with SLN mRNA expression,
which supports their use for the detection of SLN in tissue homo-
genates by Western blotting. It is clear that the SLN expression
pattern differs between larger and smaller animals. SLN protein is
expressed in skeletal muscle of pig and rabbit (1–3-fold excess of
SERCA compared with SLN), but this is not the case for mouse
or rat.
On the other hand, atria of mouse and rat present the highest
SLN to SERCA protein ratios (1.5-fold molar excess) compared
with all other tissues, whereas SLN protein appeared to be lacking
in pig and rabbit atria. It is important to note that, when found in
the atria, SLN is expressed in the absence of detectable SERCA1.
Although Minamisawa et al. [5] demonstrated very weak
SERCA1 mRNA levels in the atria of mouse, we show that this
is likely to be irrelevant compared with the abundant SERCA2
expression. Furthermore, we failed to detect SERCA1 protein
via Western blotting in microsomes of murine atria (results not
shown).
Earlier studies reported SLN expression in heart of rat [17] and
human [6], without making the distinction between atria and ven-
tricles. However, more recent publications [5,7] and the present
paper make it clear that SLN expression in the heart of all studied
species is confined to the atria, and that in the ventricles no
SLN is expressed. Also, atrial expression of SLN appears to be
significant in small mammals only. In line with this observation,
SLN mRNA expression in human atria was reported to be much
lower compared with skeletal muscle [5]. In our present study,
we did not include human muscle types, because the amino acid
sequence of human SLN is significantly different from SLN in
other animals, which precluded the use of the anti-SLN antibody
for human.
Taken together, our data show that the traditional view of SLN
as the physiological regulator of SERCA1, in contrast with PLB as
the corresponding SERCA2 inhibitor, is oversimplified. In vivo,
both PLB and SLN can be found in co-expression with either
SERCA isoform. Since in vitro, both regulators inhibit SERCA1
and SERCA2a to the same extent, a similar situation can be
expected in vivo. Indeed, artificial overexpression of SLN in the
ventricle (SERCA2a) [18] or soleus (SERCA1) of rat [15] leads
to impaired Ca2+ uptake and reduced contractility. And recently,
adenoviral overexpression of NF-SLN in rat ventricular cardio-
myocytes decreased cell shortening and the half-time of Ca2+
removal [7]. In addition, this study showed that overexpressed
NF-SLN is co-localized with PLB in the sarcoplasmic reticulum
of ventricular cardiomyocytes, indicating that both regulators can
be present in the same subcompartments of cardiac sarcoplasmic
reticulum [7].
SLN and PLB are co-expressed in the atria of rat and mouse
and in rabbit soleus
In all species, the ventricles express the highest levels of PLB. In
smaller animals, the PLB/SERCA protein ratio is three times
lower in the atria compared with the ventricle, whereas, in larger
animals, this trend is less pronounced (2-fold reduction). The
3-fold reduction in the PLB/SERCA protein ratio in murine atria
compared with ventricles is in agreement with previous results at
the mRNA level [19]. This lower ratio is the result of a higher
level of SERCA and a lower level of PLB per µg of protein in
atria compared with ventricles, which is an apparently general
characteristic common to all mammals [13]. It explains the faster
rate of Ca2+ removal in atria compared with ventricles [20]. It
therefore came as a surprise to find the highest SLN/SERCA
mRNA and protein ratio in the atria of rat and mouse (1.5-fold
molar excess), which would allow a PLB–SLN interaction and
thereby superinhibition of SERCA. Moreover, the SLN/PLB
molar ratio was 0.8 and 0.5 in atria of mouse and rat respectively,
indicating that PLB–SLN interaction may occur.
It should be noted that the overall impact of the high atrial
SLN levels in the context of PLB is difficult to evaluate and de-
pends on the mutual relative affinities in the ternary PLB–SLN–
SERCA complex. The fact that SLN acts to dissociate PLB penta-
mers should thereby not be overlooked. It is also not yet known
how PLB phosphorylation influences PLB–SLN interaction, nor
to what extent the PLB–SLN complex resists phosphorylation. In
the ventricles of SLN transgenic mice, the reduced apparent Ca2+-
affinity of SERCA might at least in part be ascribed to a decrease
in PLB phosphorylation [18]. Together, this could imply that
the actual SERCA inhibition by the PLB–SLN complex is less
pronounced than anticipated from in vitro studies.
Although SLN is probably not regulated by phosphorylation
[4], it is possible that atrial SLN helps to fine-tune the β-adren-
ergic response. Remarkably, the β-adrenergic response is known
to be different in atria compared with ventricles [19]. Koss
et al. [19] and Freestone et al. [21] proposed that the lower PLB
content of atria correlates with a smaller β-adrenergic response of
the relaxation time. In contrast, Kaasik et al. [22] observed in isol-
ated rat atria, a larger β effect on Ca2+-uptake and the relaxation
rates than in ventricle. This discrepancy may be explained by
other differences, like the higher sensitivity of atria to β stimu-
lation [19], or by the opposite frequency dependence of β-adr-
energic responsiveness in atria and ventricles [22]. Taken together,
conditions in which there is a higher or a more sensitive adrenergic
effect in the atria may result from the relief of combined SLN–
PLB inhibition on SERCA instead of from PLB alone. But future
studies in SLN targeted and transgenic mice are required to ex-
plore this hypothesis.
In addition to the atria of rodents, PLB and SLN proteins are also
co-expressed in soleus and EDL of rabbit and pig. The SLN/PLB
molar ratios are the highest in EDL of rabbit and pig, which
contain very low levels of PLB. In soleus of rabbit and pig, a SLN/
PLB ratio closer to 1 was found, suggesting a possible PLB–
SLN interaction. However, it remains to be determined whether
PLB and SLN are present in the same fibre type.
No SLN up-regulation in the heart of PLB−/− mice
The anti-SLN antibody was used to compare the expression of
SLN in different mouse models. It was interesting to find that as
a consequence of the loss of PLB, there is no compensatory up-
regulation in SLN expression in the atria or ventricles of PLB−/−
mice. PLB−/− can therefore serve as a good model for SLN study
in the absence of PLB.
SLN may contribute to altered Ca2+ handling in left
ventricular hypertrophy
Interest is growing in the role of SLN in cardiac disease. In patients
with chronic atrial fibrillation, SLN mRNA is down-regulated in
the right atrial myocardium [8]. Reduced SLN mRNA levels are
also observed in the atria of activated H-Ras transgenes develop-
ing left ventricular hypertrophy [5]. In the heart of hyperthyroid-
and thyroid-hormone-resistant mice, SLN mRNA levels are re-
spectively decreased and increased [23]. However, a discrepancy
might exist between changes at the mRNA and protein level, thus it
remains to be determined whether these differences at the mRNA
level are also observed at the protein level. In SERCA2b/b mice,
SLN down-regulation at the mRNA level was accompanied by a
similar decrease in protein level. Adult SERCA2b/b mice develop
left ventricular hypertrophy as a consequence of the expression of
c© 2005 Biochemical Society
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SERCA2b in atria and ventricles instead of the usual SERCA2a.
Taken together, it seems that altered SLN expression may contri-
bute to altered Ca2+ handling in several cardiomyopathies.
In conclusion, the generation of anti-SLN antibodies enabled us
for the first time to study the endogenous SLN protein in muscle
types of different animals and will be an important tool for future
SLN research. In larger animals, SLN is expressed in the soleus
and EDL, whereas, in rodents, SLN expression is abundant in the
atria, where it could interact with PLB and SERCA2a, but it is
less abundant in skeletal muscle. The present study also suggests
that altered SLN expression could contribute to impaired Ca2+
handling under pathological conditions.
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